Kanamycin A

Mechanism of Action:
Kanamycin works by interfering with protein synthesis. It binds to the 30S subunit of the bacterial ribosome. This results in incorrect alignment with the mRNA and eventually leads to a misread that causes the wrong amino acid to be placed into the peptide.

Brands of Kanamycin in Kenya:

Dawa-cin®, Dawa
Kanamed , Medisel Kenya Ltd
Kanamycin is a mixture of three main components: kanamycin A, B, and C. Kanamycin A is the major component in kanamycin
Kanamycin was first isolated in 1957 by Hamao Umezawa from the bacterium Streptomyces kanamyceticus


Kanamycin is indicated for short term treatment of bacterial infections caused by one or more of the following pathogens: E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, and Acinetobacter species. In cases of serious infection when the causative organism is unknown, Kanamycin injection in conjunction with a penicillin– or cephalosporin-type drug may be given initially before obtaining results of susceptibility testing.
Kanamycin does not treat viral infections


Documented hypersensitivity


Serious side effects include ringing in the ears or loss of hearing, toxicity to kidneys, and allergic reactions to the drug.
Other side effects include:
Gastrointestinal effects
Nausea, vomiting, diarrhea
Musculoskeletal effects
Myasthenia gravis
Neurologic effects
Blurring of vision
Neuromuscular blockade
Metabolic effects
Malabsorption syndrome

Clinical | Pharmacokinetic data

Pregnancy Category:
Routes of Administration:
Protein Binding:
Onset of Action:
Elimination Half life:

Legal Status | Dosage forms & Strengths

Prescription Category:

Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:

Dosage Forms | Strengths:

Drug Indentifiers:

Drug Images

References/ Citation: